Mazdutide 99% Injection Peptide Raw peptides powder GLP-1 loss weight peptide CAS2259884-03-0

Mazdutide

Mazdutide;Mazdutide acetate;Mazdutide 10mg;Mazdutide 5mg 10mg;LY-3305677;Mazdutide (IBI-362;OXM-3)

2259884-03-0

0

884-103-0

White to off-white

Inhibitors

Dual GLP-1R/GCGR agonist (long-acting peptide)

Investigational — Phase 3 (China)

A long-acting dual agonist of the GLP-1 receptor (GLP-1R, Ki = 28.6 nM) and glucagon receptor (GCGR, Ki = 17.7 nM). The dual activation provides both glycemic control (via GLP-1R) and increased energy expenditure / hepatic lipolysis (via GCGR), producing weight loss beyond what GLP-1R agonism alone achieves.

28.6 nM

17.7 nM

GlpBio: Mazdutide (CAS 2259884-03-0); Innovent Phase Ib results (eClinicalMedicine 2022).DOI

NCT04930343; NCT05592656

PubChem

GlpBio: Mazdutide (CAS 2259884-03-0); eClinicalMedicine: Innovent Phase Ib results (2022); ClinicalTrials.gov: DREAMS-1 (NCT04930343)

Mazdutide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials in China. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.